4183.TWO EPS Bio Technology Corp.
- Market cap
- TWD 343M
- P/E
- -
- P/B
- 1.28x
- ROE
- -10.3%
- Dividend yield
- 4.65%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4183.TWO undervalued?
Graham numberThe Graham number of EPS Bio Technology Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EPS Bio Technology Corp. fundamental analysis
No fundamental analysis for EPS Bio Technology Corp. yet.
EPS Bio Technology Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EPS Bio Technology Corp.
EPS Bio Technology Corp. manufactures and sells OEM/ODM blood glucose system in Taiwan. It also provides test strip; diabetic self-monitoring blood glucose systems under the EASYMAX and MDT2 BLE name; and wearable, and NFC and Bluetooth connectivity blood glucose monitors. The company was founded in 2006 and is headquartered in Hsinchu City, Taiwan.
Full company profileEPS Bio Technology Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
EPS Bio Technology Corp. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 459M | 478M | 480M | 463M | 470M | 451M | 500M | 338M |
| Gross Profit | 111M | 135M | 121M | 107M | 116M | 96.3M | 87.0M | 58.7M |
| Operating Income | 27.7M | 43.7M | 26.9M | 32.2M | 24.9M | 3.51M | -6.50M | -31.7M |
| EBITDA | 42.2M | 61.5M | 45.5M | 49.5M | 44.1M | 34.5M | 7.61M | -9.64M |
| Net Income | 18.4M | 31.7M | 18.6M | 25.4M | 21.0M | 17.3M | -7.87M | -27.5M |
| EPS | 0.77 | 1.33 | 0.78 | 1.06 | 0.88 | 0.73 | -0.33 | -1.16 |
| Balance Sheet | ||||||||
| Total Assets | 535M | 547M | 577M | 528M | 543M | 542M | 533M | 503M |
| Total Liabilities | 241M | 238M | 278M | 219M | 237M | 237M | 252M | 236M |
| Shareholders' Equity | 294M | 309M | 299M | 308M | 306M | 305M | 281M | 267M |
| Cash & Short-term Investments | 176M | 222M | 203M | 179M | 195M | 129M | 123M | 132M |
| Total Debt | 28.4M | 132M | 126M | 121M | 116M | 110M | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 21.8M | 79.9M | 32.1M | 5.00M | 55.2M | -32.3M | 603K | 37.9M |
| Capital Expenditure | 15.2M | 6.98M | 12.1M | 15.0M | 9.48M | 14.4M | 24.0M | 14.3M |
| Free Cash Flow | 6.69M | 72.9M | 19.9M | -9.96M | 45.7M | -46.7M | -23.4M | 23.6M |
| Ratios | ||||||||
| ROE | 6.3% | 10.3% | 6.2% | 8.2% | 6.9% | 5.7% | -2.8% | -10.3% |
| ROA | 3.4% | 5.8% | 3.2% | 4.8% | 3.9% | 3.2% | -1.5% | -5.5% |
| Net Profit Margin | 4.0% | 6.6% | 3.9% | 5.5% | 4.5% | 3.8% | -1.6% | -8.1% |
| Debt to Equity | 0.10x | 0.43x | 0.42x | 0.39x | 0.38x | 0.36x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
EPS Bio Technology Corp. dividends
- Dividend yield
- 4.65%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 28, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 15.9M | 0.67 | - |
| 2024 | TWD 19.0M | 0.80 | 110.0% |
| 2023 | TWD 23.3M | 0.98 | 111.1% |
| 2022 | TWD 16.7M | 0.70 | 65.7% |
| 2021 | TWD 28.6M | 1.20 | 153.2% |
| 2020 | 16.7M | 0.70 | 52.6% |
| 2019 | 16.7M | 0.70 | 90.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1040:1000 on Oct 8, 2014.
Who owns EPS Bio Technology Corp.
- Insiders 57.56%
- Institutions 0.00%
- Public & others 42.44%
- Shares outstanding 23.8M
- Free float 7.39M
EPS Bio Technology Corp. company profile
- Company name
- EPS Bio Technology Corp.
- Ticker
- 4183.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 108
- Fiscal year end
- December
- Address
- No. 8, R&D Road III, Hsinchu City, Taiwan, 30076
- Phone
- 886 3 668 6868
- Website
- epsbio.com
About EPS Bio Technology Corp.
EPS Bio Technology Corp. manufactures and sells OEM/ODM blood glucose system in Taiwan. It also provides test strip; diabetic self-monitoring blood glucose systems under the EASYMAX and MDT2 BLE name; and wearable, and NFC and Bluetooth connectivity blood glucose monitors. The company was founded in 2006 and is headquartered in Hsinchu City, Taiwan.
EPS Bio Technology Corp. management
6- Cheng-Hui ChoPresident
- Mr. Po-Hsiung KuoDeputy GM, CFO & Director
- Zhitai HuangAccounting Supervisor
- Chih-Tai HuangController
- Ching-Nien LoVice President
- Cheh-Heng LinVice President